ELVN - Enliven Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$70.25
DETAILS
HIGH:
$80.00
LOW:
$59.00
MEDIAN:
$71.00
CONSENSUS:
$70.25
UPSIDE:
39.25%
About Enliven Therapeutics, Inc. (https://www.enliventherapeutics.com)
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Samuel S. Kintz | Co-Founder & Head of Pipeline | 1986 | $956,094 USD |
| Helen Louise Collins | Chief Medical Officer | 1963 | $726,420 USD |
| Joseph Lyssikatos | Co-Founder & Research Fellow | 1965 | $709,400 USD |
| Richard A. Fair | CEO, President & Director | 1969 | $672,656 USD |
| Benjamin Hohl | Chief Financial Officer & Head of Corporate Development | 1989 | $667,894 USD |
| Anish Patel | Co-Founder & Chief Operating Officer | 1981 | – |
| Damiette Smit | Vice President of Clinical Development | – | – |
| Galya D. Blachman | Chief Legal Officer & Head of Business Development | 1977 | – |